KC
IART icon

Kepos Capital’s Integra LifeSciences IART Stock Holding History

Kepos Capital’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-5,165
Closed -$301K – 241
2019
Q4 		$301K Buy
+5,165
New +$307K 0.03% 283

Other funds holding IART

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Kepos Capital's IART Position: Q1 2020 in Review

Kepos Capital sold out of Integra LifeSciences (IART) in Q1 2020, closing a stake of 5,165 shares — an estimated $301K sold.

Kepos Capital first reported a position in IART in Q4 2019 and held it in 1 quarter. The position peaked at $301K in Q4 2019. 258 funds tracked by Wall St. Rank hold IART as of Q1 2020.

  • Kepos Capital reported no remaining Integra LifeSciences position as of Q1 2020 after selling out during the quarter.
  • Kepos Capital sold 5,165 Integra LifeSciences shares in Q1 2020, an estimated $301K.
  • Kepos Capital first reported a position in Integra LifeSciences in Q4 2019 and held it in 1 quarter.
  • Kepos Capital's Integra LifeSciences position peaked at $301K in Q4 2019.
  • 258 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2020.

Based on Kepos Capital's 13F filing for Q1 2020, filed 12 May 2020.